| OGTT | Oral Glucose Tolerance Test |
|---|---|
| OHA | Oral Hypoglycemic Agents |
| OPV | Oral Polio-Vaccine; °æ±¸¿ë ¼Ò¾Æ¸¶ºñ ¹é½Å |
| TOPV | Trivalent Oral Polio(myelitis) Vaccine; °æ±¸¿ë ¼Ò¾Æ¸¶ºñ È¥ÇÕ¹é½Å |
| WHO ORS | World Health Organization Oral Rehydration Solution osmolality 330; ¼¼°èº¸°Ç±â±¸ °æ±¸ ¼ö¾× ¿ë¾× |
| oral surgical procedures, preprosthetic | Surgery necessary for a denture to rest on a firm base, free from marked osseous protuberances or undercuts, and devoid of interfering muscle attachments, excess mucoperiosteum, hyperplasias, and fibrous or papillary growths. (12 Dec 1998) |
|---|---|
| oral teeth | <dentistry> Your centrals, laterals, and cuspids. These are the teeth in the front of your mouth. (08 Jan 1998) |
| oral ulcer | A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (stomatitis, aphthous), noma, necrotizing gingivitis (gingivitis, necrotizing, ulcerative), toothbrushing, and various irritants. (12 Dec 1998) |
| oral vestibule | That part of the mouth bounded anteriorly and laterally by the lips and the cheeks, posteriorly and medially by the teeth and/or gums, and above and below by the reflections of the mucosa from the lips and cheeks to the gums. Synonym: vestibulum oris, buccal cavity, vestibule of mouth. (05 Mar 2000) |
| tuberculosis, oral | Tuberculosis of the mouth, tongue, and salivary glands. (12 Dec 1998) |
| florid oral papillomatosis | Diffuse involvement of the lips and oral mucosa with benign squamous papillomas; microscopically, it resembles verrucous carcinoma, but is not invasive or localised to a specific area of the oral mucosa. (05 Mar 2000) |
| leukoedema, oral | A disorder of the buccal mucosa resembling early leukoplakia, characterised by the presence of filmy opalescence of the mucosa in the early stages to a whitish gray cast with a coarsely wrinkled surface in the later stages, associated with intracellular oedema of the spinous or malpighian layer. (12 Dec 1998) |
| leukoplakia, oral | A white patch seen on the oral mucosa. It is considered a premalignant condition and is often tobacco-induced. When evidence of epstein-barr virus is present, the condition is called hairy leukoplakia (leukoplakia, hairy). (12 Dec 1998) |
| lichen planus, oral | Oral lesions accompanying cutaneous lichen planus or often occurring alone. The buccal mucosa, lips, gingivae, floor of the mouth, and palate are usually affected (in a descending order of frequency). Typically, oral lesions consist of radiating white or gray, velvety, threadlike lines, arranged in a reticular pattern, at the intersection of which there may be minute, white, elevated dots or streaks (wickham's striae). (12 Dec 1998) |
| live oral poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| acupuncture therapy | Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. Heat or moxibustion and acupressure may be used in conjunction. (12 Dec 1998) |
| adjuvant therapy | <oncology, pharmacology> Treatment that is added to increase the effectiveness of a primary treatment. In cancer, adjuvant treatment usually refers to chemotherapy, hormonal therapy or radiation therapy after surgery to increase the likelihood of killing all cancer cells. (14 May 1997) |
| alternative therapy | A term given to nonconventional therapy usually given by persons who do not have a medical qualification. (16 Dec 1997) |
| analytic therapy | Short term for psychoanalytic therapy. (05 Mar 2000) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|